Main scientific publications (Dr Ariel Beresniak)

  • TABOULET F, LENOIR G, CARTRAUD A, BERESNIAK A. Intérêt économique des enquêtes de prescription : une application à l’évaluation de l’incidence économique des effets indésirables de l’antibiothérapie chez l’enfant. Journal d’Économie Médicale 1995; 13 (5):247-257.
  • TIBI-LEVY Y, DEPOUVOURVILLE G, GOURSOT G, CLERGUE F, DELEMONTEY B, FEISS F, LAXENAIRE MC, MARTY J, BERESNIAK A. Évaluation du coût direct théorique d’un passage en salle de surveillance post-interventionnelle. Annales Françaises d’anesthésie et de réanimation 1996;15:1113-120.
  • BERESNIAK A, TABOULET F, DURU G. Rationalité de la décision et choix éthique. Journal d’Économie Médicale 1996; 14(1)45-52.
  • CARRERE M.O,LAMOULIATTE H, RUSZNIEWSKI P, BERESNIAK A, SLAMA A. Traitement de l’ulcère duodénal par éradication d’Helicobacter pylori en multithérapie: modélisation et analyse coût-efficacité. Sciences Sociales et Santé 1996;14(4):37-64.
  • BERESNIAK A, TABOULET F. Évaluation de la iatrogénie médicamenteuse par les techniques de modélisation médico-“conomiques.Thérapie1997;52;59-63.
  • TIBI-LEVY Y, DEPOUVOURVILLE G, ROZENHOLC Y, GOURSOT G, CLERGUE F, DELEMONTEY B, FEISS P, LAXENAIRE MC, MARTY J, BERESNIAK A. Evaluation of Benefits related to reduced length of stays in post-anesthesia care units. International Journal of Technology Assessment in health Care 1998; 14(1):172-179.
  • BERESNIAK A, AURAY JP, FONTENEAU R. Évaluation de l’impact sur l’emploi de l’activité en santé. Journal d’Economie Médicale 1998;16(3):221-238.
  • LEVY E, AURAY JP, BAIL JN, BERAUD C, BERESNIAK A, et al. Recommandations de bonnes pratiques des méthodes d’évaluation économique des stratégies thérapeutiques. Journal d’Économie Médicale 1998; 16 (4-5) :329-351.
  • LEVY E, AURAY JP, BAIL JN, BERAUD C, BERESNIAK A, et al. Guidelines and Recommendations for French PharmacoEconomic Studies. Journal d’Économie Médicale 1998;16(4-5) :353-372.
  • LAUNOIS R, MARTY J ,PAYNE S, BERESNIAK A. Cost Effectiveness of Ondansetron and Metocloprampide in the Treatment of Post-Operative Nausea and Vomiting in Patients Undergoing Elective Surgery.Journal of Applied Therapeutic Research 1998;2:.15-22.
  • BERESNIAK A, BOUVENOT G.Utilisation de la pharmacoéconomie en antibiothérapie.Médecine et Maladies Infectieuses 2000;30:133-140.
  • TABOULET F, BERESNIAK A. Pharmacoeconomics as a tool for the synthesis of available information on drugs. Thérapie. 2000: 55(1):119-22.
  • BERESNIAK A, BOUVENOT G. Significance of Pharmacoeconomics. La Presse Médicale 2000;29(23):1299-301.
  • DAYA S, LEDGER W, AURAY JP, DURU G, SILVERBERG K, WIKLAND M, BOUZAYEN R, HOWLES CM, BERESNIAK A. Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Human Reproduction 2001;16 (12):2563-2569.
  • SILVERBERG K, DAYA S, AURAY JP, DURU G, LEDGER W, WIKLAND M, BOUZAYEN R, O’BRIEN M, FALK B, BERESNIAK A. Analysis of the cost-effectiveness of recombinant versus urinary follicle stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertility and Sterility, 2002;77(1)107-113.
  • DURU G, AURAY JP, BERESNIAK A, LAMURE M, PAINE A, NICOLOYANNIS N. Limitations of the methods used for calculating quality-adjusted life years values. Pharmacoeconomics 2002;20(7):463-73.
  • SIMEONI MC, BLUMHARDT L, FERNANDEZ O, FLACHNECKER P, PELLETIER J, STECCHI S, BERESNIAK A, AUQUIER P. International Development of a Patient-Centered QOL Scale for MS. Journal of MS Care 2002.
  • FELBERBAUM R, DAYA S, FISHER R, THAELE M, AURAY JP. DURU G, BOUZAYEN R, BERESNIAK A, BLESCHSCHMIDT J. Cost-effectiveness modeling of Recombinant FSH (r-hFSH) Versus Urinary FSH (u-hFSH) in Assisted Reproduction Techniques (ART) in Germany. Geburtsh Frauenhelk, 2002:62:668-676.
  • BARRI P, BALASCH J, ROMEU A, BALDA JAR, DAYA S, AURAY JP, DURU G, BERESNIAK A, PEINADO JA. Cost-effectiveness of recombinant and urinary follicle-stimulating hormone in assisted reproduction techniques in the private health sector in Spain. Revista Iberoamericana de Fertilidad 2002: 19(3):195-202.
  • SILVERBERG K, SCHERTZ J, FALK B, BERESNIAK A. Impact of urinary FSH price : a cost-effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA. RBM online 2002; 5(3): 265-269.
  • BREMOND-GIGNAC D, TIXIER J, MISSOTTEN T, LAROCHE L, BERESNIAK A. Evaluation of the Quality of Life in Ophtalmology, Presse Med. 2002;31(34):1607-1612.
  • FONTENEAU R, BERESNIAK A. Les Limites de la planification sanitaire en Afrique subsaharienne.Journal d’ Économie Médicale 2002;20(7-8):445-454.
  • LEPEN C, COYLE P, VOLMER T, BLUMHARDT L, LILLIU H, BERESNIAK A. Long-Term Cost Effectiveness of Interferon-Beta 1a in the Treatment of Relapsing-Remitting Multiple Sclerosis, An Economeric Model.Clinical Drug Investigation 2003;23(9):571-581.
  • DAYA S, WIKLAND M, SILVERBERG KM, BLATZ S, DURU G, BERESNIAK A. Quality of life (QOL) differentiation analysis in patients undergoing controlled ovarian stimulation (COS) with two different preparations of recombinant human follicle-stimulating hormone (r-hFSH), Fertility and Sterility 2003;80(Suppl.3).137-137(1).
  • ROMEUS A, BALASCH J, RUIZ BALDA JA, BARRI PN, DAYA S, AURAY JP, DURU G, BERESNIAK A, PEINADO JA. Cost-effectiveness of recombinant versus urinary follicule stimulating hormone in assisted reproduction techniques in the Spanish public health care system. Journal of Assisted Reproduction and Genetics 2003;20(8):294-300.
  • CRAMER JA, SIMEONI MC, ROBITAIL S, AUQUIER P, BRASSEUR P, BERESNIAK A. Development of a growth hormone injection questionnaire for adolescents. J Adolesc Health 2004 34(1):27-9.
  • BERESNIAK A. Pharmacoeconomic advantages of recombinant FSH vs urinary drived. Gynecol Obset Fertil 2004;32(9):756-9.
  • TAYLOR B, MCDONALD E, PITTAS F, GROOM T, FANTINO B, SEDAL L, MACDONNELL R, BERESNIAK A. Multiple Sclerosis 2004;10(Suppl.2):133-138(6)
  • BERESNIAK A. Testing assumptions of quality-adjusted life-year calculations – Commentary: An Exponential representation of Health State Utility. Eur J Health Econ 2004;4(4):295. Epub 2003 Jun 21.
  • CRAMER JA, SIMEONI MC, AUQUIER P, ROBITAIL S, BRASSEUR P, BERESNIAK A. Brief report : a quality of life instrument for adolescents with growth disorders. J Adolesc. 2005 28(4): 595-600.
  • DEVOGELAERE T, BERESNIAK A, RAYMAECKERS A, NAACKE H, YAN KAI S, BREMOND-GIGNAC D. Clinical study of Supranettes pads in the treatment of seasonal or perennial allergic conjunctivitis in children. J Fr. Ophtalmol. 2006;29,6,1-6.
  • POMEY MP, FOREST PG, MARTIN E ,BERESNIAK A. Le régime général d’assurance médicaments au Québec, un partenariat public privé confronté à des défis, Journal d’Economie Médicale 2007;25 (5-6) :319-335.
  • BERESNIAK A, RUSSEL AS, HARAOUI B, BESSETTE L, BOMPARDIER C, DURU G. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007;34(11):2193-200.
  • TAYLOR B, MCDONALD E, FANTINO B, SEDAL L, MACDONNELL R, PITTAS F, GROOM T, BERESNIAK A. The cost of multiple sclerosis in Australia. J Clin Neurosci. 2007 Jun;14(6):532-9. Erratum in: J Clin Neurosci. 2008 Oct;15(10):1189. Beresniak, Ariel [added].
  • SIMEONI M, AUQUIER P, FERNANDEZ O, FLACHENECKER P, STECCHI S, CONSTANTINESCU C, IDIMAN E, BOYKO A, BEISKE A, VOLLMER T, TRIANTAFYLLOU N, OCONNOR P, BARAK Y, BIERMANN L, CRISTIANO E, ATWEH S, PATRICK D, ROBITAIL S, AMMOURY N, BERESNIAK A. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler 2008;14(2):219-230.
  • COHEN SY, BREMOND-GIGNAC D, QUENTEL G, MIMOUN G, CITTERIO T, BISOT-LOCARD S, BERESNIAK A. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration., Graefes Arch Clin Exp Ophthalmol. 2008; DOI 10.1007/s00417-008-0890-8.
  • RUSSELL A, BERESNIAK A, BESSETTE L, HARAOUI B, RAHMAN P, THORNE C, MACLEAN R, DUPONT D. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol. 2008 Published online Dec. 2008; DOI 10.1007/s10067-008-1060-4.
  • BENSMAIL D, WARD AB, WISSEL J, MOTTA F, SALTUARI L, LISSENS J, CROS S, BERESNIAK A. Cost-effectiveness Modeling of Intrathecal Baclofen Therapy Versus Other Interventions for Disabling Spasticity. Neurorehabil Neural Repair. 2009 Feb 19.
  • BOUCHARD P, RENOUARD F, BOURGEOIS D, FROMENTIN O, JEANNERET MH, BERESNIAK A. Cost-effectiveness modeling of dental implant vs. bridge. Clin Oral Implants Res. 2009;20(6):583-7.
  • BRIAND S, BERESNIAK A, NGUYEN T, YONLI T, DURU G, KAMBIRE C, PEREA W. The Yellow Fever Risk Assessment Group (YF-RAG), Assessment of Yellow Fever Epidemic Risk: An Original Multi-criteria Modeling Approach. PLoS Negl Trop Dis. 2009;14;3(7):e483.
  • BREMOND-GIGNAC D, MARIANI-KURKDJIAN P, BERESNIAK A, EL FEKIH L, BHAGAT Y, POULIQUEN P, DELVAL L, GOLDSCHMIDT P, BINGEN E, COCHEREAU I. Efficacy and Safety of Azithromycin 1.5% Eye Drops for Purulent Bacterial Conjunctivitis in Pediatric Patients. Pediatr Infect Dis J. 2009 Nov 20.
  • FARDELLONE P, CORTET B , LEGRAND E, BRESSE X, BISOT-LOCARD S, VIGNERON AM, BERESNIAK A. Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in post-menopausal osteoporosis. Joint Bone Spine 2010; 77: 53–57.
  • SARAUX A, GOSSEC L, GOUPILLE P, BREGMAN B, BOCCARD E, DUPONT D, BERESNIAK A. Cost-Effectiveness Modelling of Biological Treatment Sequences in Moderate to Severe Rheumatoid Arthritis in France. Rheumatology (Oxford) 2010; 49(4): 733-40.
  • BERESNIAK A, GOSSEC L, GOUPILLE P, SARAUX A, BAMBERGER M, BREGMAN B, DUPONT D. Direct Cost-Modeling of Rheumatoid Arthritis According to Disease Activity Categories in France.  J Rheumatol March 1, 2011 38(3):  439-445; (published online before print December 1 2010, doi: 10.3899/jrheum.100589).
  • CIMMINO M, LEARDINI G, SALAFFI F,  INTORCIA M, BELLATRECCIA A, DUPONT D, BERESNIAK A.  Assessing the cost-effectiveness of biologic agents for the management of moderate to severe rheumatoid arthritis in anti-TNF inadequate responders in Italy:   a modelling approach.  Clin Exp Rheumatol. 2011 Jul-Aug;29(4):633-41. Epub 2011 Aug 31.
  • BERESNIAK A, ARIZA-ARIZA R, GARCIA-LLORENTE JF, RAMIREZ ARELLANO A, DUPONT D. Modelling Cost-Effectiveness of Biologic Treatments based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain. International Journal of Inflammation  2011; doi:10.4061/2011/727634.
  • KALRA D, SCHMIDT A, POTTS HWW, DUPONT D, SUNDGREN M, DE MOOR G, on behalf of the EHR4CR Research Consortium. Case Report from the EHR4CR Project – A European Survey on Electronic Health Records Systems for Clinical Research. iHealth Connection 2011; 1(2): 108-13.
  • BERESNIAK A, BERTHERAT E, PEREA W, SOGA G, SOULEY R, DUPONT D, HUGONNET S. A Bayesian network approach to the study of historical epidemiological databases: modelling meningitis outbreaks in the Niger. Bull World Health Organ 2012; 90: 412-17A. doi: 10.2471/BLT.11086009
  • BERESNIAK A, BAERWALD C, ZEIDLER H, KRÜGER K, NEUBAEUR AS, DUPONT D, MERKESDAL S. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clin Exp Rheumatol 2013; 31(3): 400-8.
  • COOREVITS P, SUNDGREN M, KLEIN GO, BAHR A, CLAERHOUT B, DANIEL C, DUGAS M, DUPONT D, SCHMIDT A, SINGLETON P, DE MOOR G, KALRA D. Electronic health records: new opportunities for clinical research. Journal of Internal Medicine 2013; June: doi:10.1111/joim.12119. 
  • BERESNIAK A. Public health. Be prepared: what works in fight against flu. Health Serv J. 2014 May 23;124(6399):19-21.
  • DE MOOR G, SUNDGREN M, KALRA D, SCHMIDT A, DUGAS M, CLAERHOUT B, KARAKOYUN T, OHMANN C, LASTIC PY, AMMOUR N, KUSH R, DUPONT D, COOREVITS P. Using Electronic Health Records for Clinical Research: the Case of the EHR4CR Project. Journal of Biomedical Informatics 2014 (In press).
  • BERESNIAK A, MEDINA-LARA A, AURAY JP, DE WEVER A, PRAET JC, TARRICONE R, TORBICA A, DUPONT D, LAMURE M, DURU G. Validation of the Underlying Assumptions of the QALY Indicator: Results from the ECHOUTCOME European Project. Pharmacoeconomics 2014 (In press).
  • BERESNIAK A, AURAY JP, DURU G, ARACTINGI S, KRUEGER G, TALARICO S, TSUTANI K, DUPONT D, DE LINARES Y. (2015), Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument. Journal of Cosmetic Dermatology, 14: 260–265. doi: 10.1111/jocd.12156.
  • BERESNIAK A, AURAY JP, DURU G, ARACTINGI S, KRUEGER G, TALARICO S, ADAM AS, PLOT B,  DUPONT D, DE LINARES Y. Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL  instrument. J Cosmet Laser Ther. 2015 Jul 2:1-5. [Epub ahead of print] dpi10.3109/14764172.2015.1039034
  • BERESNIAK A, CARUBA T, SABATIER B, JUILLIERE Y, DUBOURG O, DANCHIN N. Cost-effectiveness modelling of percutaneous coronary interventions in stable coronary artery disease. World J Cardiol 2015 October 26; 7(10): 594-602.
  • BERESNIAK et al. Assessing the Hair Colourings’ Impact on Quality of Life. Cosmo Trichol 2015, 1:1. http://dx.doi.org/10.4172/jctt.1000103.
  • DUPONT D, BERESNIAK A, SCHMIDT A, PROEVE J, BOLANOS E, AMMOUR N, SUNDGREN M, ERICSON M, KALRA D, DE MOOR G. Assessing the Financial Impact of Reusing Electronic Health Records Data for Clinical Research: Results from the EHR4CR European Project. J Health Med Informat 2016; 7 (3): 235. doi:10.4172/2157-7420.1000235.